Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regulus Therapeutics Inc. - Common Stock (NQ: RGLS )

1.255 +0.045 (+3.72%)
Streaming Delayed Price Updated: 2:48 PM EST, Feb 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regulus Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Recap: Regulus Therapeutics Q4 Earnings
Regulus Therapeutics (NASDAQ:RGLS) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
Regulus Therapeutics's Earnings: A Preview
Regulus Therapeutics (NASDAQ:RGLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement.... 
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter. • Fulcrum Therapeutics (NASDAQ:... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
68 Biggest Movers From Yesterday
Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 39.2% to... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Trevi Therapeutics (NASDAQ:TRVI) shares rose 46.6% to $1.28 during Wednesday's regular session. As of 12:30 EST, Trevi Therapeutics's stock is trading at a... 
Via Benzinga
Executives Buy Over $6M Of 5 Penny Stocks
Although gold prices traded slightly lower to below $1,820 an ounce on Tuesday ahead of US inflation data due later in the week, there were a few notable insider trades. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Calyxt (NASDAQ:CLXT) shares rose 12.4% to $1.63 during Friday's pre-market session. The company's market cap stands at $62.7 million. Better Therapeutics (... 
Via Benzinga
5 Penny Stocks Insiders Are Buying: OpGen, Regulus Therapeutics And More
The US economy grew 6.9% on quarter during the last three months of previous year, up from 2.3% expansion in the prior quarter and also above marke... 
Via Benzinga
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura... 
Via Benzinga
Regulus Therapeutics Moves Forward With Next-Gen Compound, RGLS8429 In Kidney Disorder
Regulus Therapeutics Inc (NASDAQ: RGLS) has completed a pre-investigational new drug (Pre-IND) meeting with the FDA to obtain input on the Company's RGLS8429... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 41 stocks made new 52-week lows. Facts of Interest About Today's 52-Week Lows: Biogen (NASDAQ:BIIB) was the biggest company by market cap to set a... 
Via Benzinga
How The Future Looks For Last Week's Biggest Losers: Futu, Regulus Therapeutics And More
Last week, the five biggest stock market losers declined between about 36% and 26%. Below is a look at each stock and what they may have in the cards going forward. What To Watch... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Jumps 100 Points; Jasper Therapeutics Shares Spike Higher
Toward the end of trading Wednesday, the Dow traded up 0.06% to 34,398.86 while the NASDAQ rose 0.70% to 14,566.72. The S&P also rose, gaining 0.31% to 4,364.35. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Statera BioPharma (NASDAQ:STAB) shares increased by 16.92% to $3.16 during Wednesday's regular session. The market value of their outstanding shares is at $87.... 
Via Benzinga
Mid-Day Market Update: Gold Surges 2%; Neuronetics Shares Plunge
Midway through trading Wednesday, the Dow traded down 0.43% to 34,229.72 while the NASDAQ rose 0.40% to 14,524.02. The S&P also fell, dropping 0.10% to 4,346.21. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
50 Biggest Movers From Yesterday
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating... 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7... 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
Exposures Product Safety
20 Stocks Moving in Wednesday's Pre-Market Session
Gainers Puxin Limited (NYSE: NEW) rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday. Jasper Therapeutics, Inc. (NASDAQ: JSPR) rose 38% to $9.95 in pre-... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021
Upgrades For Okta Inc (NASDAQ: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Celularity (NASDAQ:CELU) shares rose 7.0% to $7.33 during Tuesday's after-market session. The market value of their outstanding shares is at $904.9... 
Via Benzinga
Recap: Regulus Therapeutics Q2 Earnings
Shares of Regulus Therapeutics (NASDAQ:RGLS) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 65.22% year... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Nuwellis (NASDAQ:NUWE) shares in... 
Via Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Alterity Therapeutics (NASDAQ:ATHE) shares rose 13.66% to $1.58 during Thursday's pre-market session. The market value of their outstanding shares is at $63.3... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.